Introduction
Modern technology allows us to measure nearly every biological parameter. However, in her book Bad Influence, Deborah Cohen warns against the optimization trap. This is a phenomenon where measurable data ceases to be a diagnostic tool and instead becomes an autonomous goal in its own right.
The reader will discover how wearable devices and modern pharmacology are shifting our approach to health. This text analyzes the risk of equating digital metrics with actual well-being and the process of subordinating the body to algorithmic norms.
Self-Monitoring Technology as an External Behavioral Regulation System
Health trackers create a loop: measurement – interpretation – action. Deborah Cohen notes that these devices are not passive observers; rather, they become external control systems for our habits.
Paradoxically, the effectiveness of these tools leads to problems. When a user begins striving to "close the ring" in an app, intrinsic motivation is replaced by reward substitution. An example of this is when a walk loses its perceived value if it was not recorded by a device.
As a result, the individual stops optimizing for health and starts optimizing for a numerical score. This leads to a situation where the metric dominates the actual state of the organism.
The Risk of Subject Reification through the Algorithmic Authority of Numbers
Self-monitoring technologies can distort health consciousness through reification. This occurs when a simplified indicator (e.g., a sleep score) begins to be treated as the sole truth about the body, replacing subjective feelings.
Deborah Cohen points to the risk of orthosomnia—the obsessive pursuit of a perfect sleep score. Such a focus on data can paradoxically increase anxiety and make it harder to fall asleep, thereby worsening the user's psychological well-being.
In the case of CGM (continuous glucose monitoring), the problem lies in the illusion of precise dietary tailoring. The author emphasizes that a single glycemic curve is not a substitute for nutritional science, and attempting to flatten every peak can lead to erroneous dietary choices.
Weight Management Pharmacology: From Monitoring to Direct Biological Modification
Modern medications, such as GLP-1 and GIP/GLP-1 agonists, fit into the optimization trap by blurring the line between therapy and aesthetics. While they have a legitimate medical basis for treating obesity as a chronic disease, they are increasingly becoming tools for social conformity.
Deborah Cohen warns about the influence of social media and the feed, where "before and after" photos promote a pharmacological pursuit of an ideal. Human agency is replaced by an external benchmark, and treatment becomes a product of appearance optimization.
The necessity for long-term use of these drugs stems from the nature of the disease and biological appetite regulation mechanisms, rather than addiction. However, this model creates a market for lifelong customers, raising questions about ethics and access to therapy.
Summary
In a world of permanent feedback, we risk losing the ability to live outside the regime of constant correction. Deborah Cohen reminds us that health is primarily about adaptive freedom, not total compliance with an algorithmic norm.
The greatest challenge of the future will be maintaining autonomy in the face of technology. True luxury may become the right to be imperfect in a way that no sensor would categorize as an error.
Frequently Asked Questions
How do health trackers work, and why can their effectiveness paradoxically lead to optimization problems?
Health trackers function as regulatory systems, creating a feedback loop (measurement – interpretation – action) that modifies user behavior. Optimization problems arise when the metric becomes an autonomous goal and the individual begins to subordinate their actions to the metric itself rather than to actual biological needs.
How can self-monitoring technologies lead to a distortion of health care?
These technologies can lead to situations where the user optimizes their actions based on algorithmic indicators (e.g., recovery scores or glucose charts) rather than the actual state of health and physical fitness. This results in equating a simplified measurement with a person's overall condition, shifting focus from real well-being to the pursuit of a better numerical result.
How can health monitoring devices paradoxically impair our psychological well-being?
These devices can lead to questioning one's own feelings in favor of data and trigger anxiety and perfectionism; in the case of sleep (orthosomnia), this paradoxically makes it harder to fall asleep due to excessive control. Additionally, optimization may turn into hypervigilance, and the pursuit of immediate digital results may replace the original goal of improving health.
Does increasing step counts or monitoring glucose using trackers and CGMs automatically mean an improvement in health?
Not automatically. Tracker-type devices can effectively increase the number of steps (a proximal outcome), but it is harder to demonstrate that this translates directly into distal health outcomes, such as blood pressure or mortality.
Does real-time glucose tracking allow me to precisely tailor my diet to my body?
Tracking glucose levels alone is not equivalent to nutrition science, as a single metabolic curve does not account for key aspects of nutrition, such as energy density or micronutrients. Drawing conclusions based on CGM is risky, as the result is influenced by numerous variables (e.g., sleep, stress, physical activity), and not only by the consumed products.
How do self-monitoring technologies affect a user's sense of agency, and what are their social consequences?
Self-monitoring technologies initially increase agency by providing data, but in the long run, they may limit it, leading to a dependence on external validation and the outsourcing of self-assessment. Socially, this phenomenon promotes a neoliberal model of the human being as an optimization project and deepens inequalities (the wellth divide), where resources are directed toward excessive diagnostics for wealthy individuals at the expense of fighting systemic determinants of disease.
When does healthy body monitoring turn into an obsessive pursuit of ideal parameters?
Healthy monitoring turns into an obsessive pursuit when tools stop supporting life and start governing it, turning every activity into an investment in a future result. This happens when criteria become rigid and there is a compulsive need to correct every deviation from the norm, which narrows human agency and subordinates the individual to data rules.
How do modern weight-loss drugs fit into the mechanism of the optimization trap?
Modern weight-loss drugs fit into the optimization trap because they allow for the direct modification of body mass—a parameter that is easily measurable and highly visible socially. As a result, technology that serves as a breakthrough treatment for metabolic diseases is adopted by the aspirational market as a tool for unlimited appearance optimization.
Are modern weight-loss drugs merely a pharmacological fad, or do they have a real medical justification?
Modern weight-loss drugs have a real medical justification and are not merely a pharmacological fad, as confirmed by studies showing significant weight reduction and a decrease in the number of serious cardiovascular events. Obesity is currently treated as a chronic disease, and the WHO has recognized GLP-1 therapy as a possible option for long-term treatment in adults.
How do modern weight-loss drugs change the perception of human agency, and where is the line between therapy and the pursuit of an aesthetic ideal?
Modern weight-loss drugs change the perception of agency by showing that body mass does not depend solely on willpower but is embedded in biological regulatory systems. The line between therapy and the pursuit of an ideal lies between treating people in risk groups (defined, among other things, by BMI and health problems) and the use of medications by people with a normal body weight to achieve aesthetic effects.
How do social media and cultural norms influence the way modern weight-loss drugs are used?
Social media promote the visual effects of treatment through 'before' and 'after' photos, making individual transformation stories a stronger argument than medical analyses. This leads to the creation of new standards of thinness and pressure for bodily conformity, where medications may be treated not as medical therapy, but as a tool for achieving social aesthetic ideals.
Does the necessity of long-term use of weight loss medications result from addiction or the nature of the disease, and what are the consequences?
The need for long-term medication stems from the fact that obesity is a chronic disease, and discontinuing the preparation may lead to weight regain by reactivating appetite regulation mechanisms. This is not evidence of pharmacological addiction, but rather a situation analogous to treating hypertension. The consequence of such a model is the creation of an exceptionally valuable market for the pharmaceutical industry from an economic perspective.
What are the social and ethical consequences of the widespread use of modern weight loss drugs?
The widespread use of these drugs may lead to shortages for patients with medical indications and deepen social inequalities (the "wellth divide"), as access to expensive therapy is primarily available to wealthy individuals. An ethical problem also arises regarding the reductionist identification of health with slimness and weight loss itself, rather than overall bodily well-being.
How does the effectiveness of modern weight loss drugs influence the social perception of body weight and the ethics of their use?
The effectiveness of new weight loss drugs may change the perception of body weight as a medical parameter, which paradoxically increases an individual's responsibility for its state and may lead to viewing a lack of correction as negligence. There is a risk that aesthetic standards will shift to a level difficult to achieve without medical intervention, making pharmacotherapy socially expected. Consequently, the ethics of using these drugs should be based on the principle of proportionality, where the justification for therapy depends on the degree of health risk and benefit, rather than solely on aesthetic goals.
What market and communication mechanisms cause weight loss drugs to stop being just a therapy and become an optimization product?
This process is driven by remote drug sales, "on demand" models, and collaborations with influencers who combine the roles of patients and business partners. A significant role is played by unbranded education campaigns funded by manufacturers and the reduction of the therapy's goal exclusively to the weight loss index.
Does the greatest weight reduction using GLP-1 drugs always mean the best health outcome, and what other areas of biology are subject to similar optimization?
The greatest weight reduction does not always mean the best health outcome, as the relationship between risk, safety, quality of life, and clinical benefits is key. Similar optimization of biological parameters occurs in the areas of sex hormones, energy, libido, mood, aging, and menopause.
